Table 1 Alteration of CD206+Rab37+ST2L+ cells in relation to clinicopathological parameters in 48 lung cancer patients’ tumor specimens.

From: IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer

Clinical

Total

CD206+Rab37+ST2L+ cells (%)

 

Parameters

Patients

Protein Expression

p-valuea

 

48

N = 24

N = 24

 

(50%)

(50%)

Low expressionb

High expressionb

Age

<65

34

15 (44.1)

19 (55.9)

0.171

≥65

14

9 (64.3)

5 (35.7)

Gender

Male

26

15 (57.7)

11 (42.3)

0.193

Female

22

9 (40.9)

13 (59.1)

Tumor stage

I-II

23

15 (65.2)

8 (34.8)

0.041

III-IV

25

9 (36)

16 (64)

T stagec

T1-2

38

21 (55.3)

17 (44.7)

0.143

T3-4

10

3 (30.0)

7 (70.0)

N stagec

≤N1

14

11 (78.6)

3 (21.4)

0.012

>N1

34

13 (38.2)

21 (61.8)

M stagec

M0

42

23 (54.8)

19 (45.2)

0.094

≥M1

6

1 (16.7)

5 (83.3)

Differentiation grade

Well

8

4 (50.0)

4 (50.0)

0.287

Moderate

32

18 (87.5)

14 (12.5)

Poor

8

2 (25)

6 (75)

Recurrence

No

13

12 (92.3)

1 (7.7)

0.001

Yes

35

12 (34.3)

23 (65.7)

  1. aThe data were analyzed by Pearson χ2 test. p-values with significance are shown as bold letters.
  2. bPatient with CD206+Rab37+ST2L+cells (%) ≥ 0.6% of ROIs were defined as high expression.
  3. cT stage: primary tumor; N stage: lymph node metastasis; M stage: distant metastasis.
Back to article page